Calliditas Therapeutics (CALT) has released an update.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Calliditas Therapeutics, a Stockholm-based biopharma company, is preparing to delist from Nasdaq Stockholm and the Nasdaq Global Select Market following Asahi Kasei’s acquisition of over 90% of its shares. The company will apply for delisting, with the last trading day to be announced post-confirmation from Nasdaq Stockholm. Additionally, an Extraordinary General Meeting is scheduled for September 30, 2024, to elect a new Board of Directors.
For further insights into CALT stock, check out TipRanks’ Stock Analysis page.
